CTC BIO said it successfully completed the phase 3 clinical trials for its combination drug One-two tab., designed to treat premature ejaculation.

The treatment is a combination therapy that integrates clomipramine HCL, used in Condensia for treating premature ejaculation, and sildenafil citrate, the active ingredient in Viagra, which is used for erectile dysfunction.

The phase 3 trial results demonstrated that the treatment significantly extended intravaginal ejaculation latency time (IELT).

Over four, eight, and 12-week intervals, the drug consistently showed statistically significant increases in IELT compared to control groups treated with either clomipramine or sildenafil alone.

In preparation for its official launch in July, CTC BIO is finalizing the treatment production processes.

“We plan to make every effort to quickly establish One-two tab. in the market and expand globally, thereby continuing our performance growth,” CTC Bio CEO Kim Young-deok said.